Organon (OGN) Accumulated Expenses (2020 - 2026)
Organon (OGN) posted quarterly Accumulated Expenses of $1.4 billion for Q2 2026, down 0.92% year-over-year from $1.4 billion in Q2 2025, and down 1.19% on a QoQ basis from $1.4 billion in Q1 2026.
Organon (OGN) Accumulated Expenses (2020 - 2026) Analysis & Trends
Organon has reported Accumulated Expenses for 7 years, with the latest figure at $1.4 billion in Q2 2026.
- Accumulated Expenses for Q2 2026 came in at $1.4 billion, down 0.92% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 0.92% YoY), and the FY2025 annual result was $1.3 billion, down 5.39% from the prior year.
- Accumulated Expenses slipped to $1.4 billion in Q2 2026, from $1.4 billion in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.5 billion in Q3 2024 and troughed at $1.0 billion in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.4 billion in 2024 frame the typical range for Accumulated Expenses.
- The widest annual swing landed in 2022, when Accumulated Expenses jumped 33.6%; it then fell 5.39% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $1.2 billion in 2022, then advanced by 16.92% to $1.4 billion in 2023, then advanced by 1.58% to $1.4 billion in 2024, then declined by 5.39% to $1.3 billion in 2025, then gained by 5.39% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $1.4 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Bn |
| Mar 31, 2026 | 1.42 Bn |
| Dec 31, 2025 | 1.34 Bn |
| Sep 30, 2025 | 1.44 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | 1.41 Bn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | 1.46 Bn |
| Jun 30, 2024 | 1.30 Bn |
| Mar 31, 2024 | 1.39 Bn |
| Dec 31, 2023 | 1.39 Bn |
| Sep 30, 2023 | 1.26 Bn |
| Jun 30, 2023 | 1.10 Bn |
| Mar 31, 2023 | 1.15 Bn |
| Dec 31, 2022 | 1.19 Bn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 1.01 Bn |
| Dec 31, 2021 | 1.02 Bn |
| Sep 30, 2021 | 1.08 Bn |